# US 2025/0164472 A1 · Magnetic separation of biological entities from fluid sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164472 A1
- Document ID: US20250164472A1
- Status: Published application
- Kind: A1
- Application number: 19/024,319
- Filed: 2025-01-16
- Published: 2025-05-22
- Earliest claimed: 2018-07-20
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Sasank VEMULAPATI; David ERICKSON
- Web page: https://patentgrep.com/patent/US20250164472A1

## CPC

- G01N 33/54326: {Magnetic particles}
- B03C 1/01: by addition of magnetic adjuvants
- B03C 1/288: {disposed at the outer circumference of a recipient}
- G01N 1/4077: {by other techniques involving separation of suspended solids}
- G01N 33/56966: {Animal cells}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- G01N 35/0098: {involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation (magnetic particles used in immunoassays G01N33/54326; magnetic separation in general B03C)}
- B03C 2201/18: Magnetic separation whereby the particles are suspended in a liquid
- B03C 2201/26: for use in medical or biological applications
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B03C: MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS (separating isotopes B01D59/00; combinations of magnetic or electrostatic separation with separation of solids by other means B03B, B07B)

## Abstract

The present disclosure relates to, inter alia, devices, systems, and methods for use in the magnetic separation of biological entities from fluid samples. This device includes a magnetic separation chamber configured to receive a fluid sample for magnetic separation, where the magnetic separation chamber includes at least two magnets mounted on the surface or in the wall of the magnetic separation chamber. The device also includes a force provider configured to move the magnetic separation chamber in a side-to-side motion to mix and/or magnetize the fluid sample. In one embodiment, the magnetic separation chamber is in a form of a sleeve and comprises a substantially central channel for loading a vessel containing the fluid sample therein. The systems and methods of the present disclosure involve the use of this device to separate biological entities from fluid samples.

## Claims

### Claim 1

A system for use in magnetic separation of a target biological entity from a blood sample, said system comprising:
a vessel comprising a tube or a container for containing the blood sample during operation;
a plurality of magnetic beads each functionalized to bind to the target biological entity;
an aggregation agent configured to induce clumping of a plurality of target biological entities to form aggregates of the target biological entities; and
a magnetic source configured to generate a magnetic field within the vessel to separate the plurality of magnetic beads from the blood sample, such that the target biological entities are substantially captured and depleted.

### Claim 2 (depends on 1)

The system according to claim 1, wherein the target biological entities are substantially captured and depleted to separate greater than 90% of the target biological entity.

### Claim 3 (depends on 1)

The system according to claim 1, wherein the aggregation agent is present at or above a critical concentration of on or about 0.75 mg/mL.

### Claim 4 (depends on 1)

The system according to claim 1, wherein the target biological entities are substantially captured and depleted to separate greater than 95% of the target biological entity.

### Claim 5 (depends on 1)

The system according to claim 1, wherein the aggregation agent is present at or above a critical concentration of on or about 1 mg/mL.

### Claim 6 (depends on 1)

The system according to claim 1 wherein the aggregation agent is present at or above a critical concentration to create a level of aggregation necessary to separate greater than 99% of the target biological entity.

### Claim 7 (depends on 1)

The system according to claim 1, wherein the aggregation agent is present at or above a critical concentration of on or about 2.5 mg/mL.

### Claim 8 (depends on 1)

The system according to claim 1, wherein said aggregation agent is selected from the group consisting of a polyclonal antibody, monoclonal antibody, a protein, dextran, polyvinylpyrollidone, polyoxyethylene, fibrinogen, immunoglobulin IgM and IgG, calcium chloride, and any combinations thereof.

### Claim 9 (depends on 1)

The system according to claim 1, wherein the magnetic beads are each functionalized with an anti-blood cell antibody that binds to red blood cells, white blood cells, platelets, or any combinations thereof, specifically or non-specifically.

### Claim 10 (depends on 1)

The system according to claim 1, wherein the aggregation agent is an antibody that binds to red blood cells, white blood cells, platelets, or any combinations thereof, specifically or non-specifically.

### Claim 11 (depends on 1)

The system according to claim 1, wherein the magnetic beads are conjugated to the aggregation agent and the aggregation agent is an antibody that binds to red blood cells, white blood cells, platelets, or any combinations thereof specifically or non-specifically.

### Claim 12 (depends on 1)

The system according to claim 1, wherein the aggregation agent is an antibody that binds to a surface marker of red blood cells selecting from the group consisting of CD235a and TER119.

### Claim 13 (depends on 1)

The system according to claim 1, wherein the target biological entity is selected from the group consisting of red blood cells, white blood cells, platelets, cell associated contaminants, waste products, and excess reagents contained in the blood sample.

### Claim 14 (depends on 1)

The system according to claim 1, further comprising a collection component for collecting a supernatant produced after capturing and separating the target biological entity from the blood sample.

### Claim 15 (depends on 1)

The system according to claim 1, wherein the vessel houses magnetic beads and dried aggregation agent.

### Claim 16 (depends on 1)

The system according to claim 1, wherein the system is configured to at least substantially homogenously distribute the magnetic beads and the aggregation agent in the blood sample.

### Claim 17 (depends on 1)

The system according to claim 1, wherein the system is configured to separate greater than 99.9% of target biological entity within 2 minutes.

### Claim 18 (depends on 1)

The system according to claim 1, further comprising a collection component configured to collect a supernatant product after the separation of the target biological entity from the blood sample, wherein the supernatant product has an average purity of greater than 99.9% and a recovery rate of greater than 90%.

### Claim 19 (depends on 1)

The system according to claim 1, wherein each functionalized magnetic bead has a plurality of functional groups, and each functional group is configured to capture a plurality of aggregated target biological entities.

### Claim 20 (depends on 1)

The system according to claim 1, wherein each magnetic bead is conjugated with a plurality of aggregation agents, each conjugated aggregation agent is configured to capture a plurality of aggregated target biological entities grouped by a plurality of unconjugated aggregation agents.
